Compare WAB & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAB | TAK |
|---|---|---|
| Founded | 1869 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 43.3B |
| IPO Year | 1995 | N/A |
| Metric | WAB | TAK |
|---|---|---|
| Price | $230.56 | $17.20 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $245.44 | N/A |
| AVG Volume (30 Days) | 656.9K | ★ 3.2M |
| Earning Date | 02-11-2026 | 01-29-2026 |
| Dividend Yield | 0.43% | ★ 3.07% |
| EPS Growth | ★ 14.53 | N/A |
| EPS | ★ 6.87 | 0.45 |
| Revenue | $10,785,000,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $8.16 | $0.47 |
| P/E Ratio | ★ $33.85 | $38.35 |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $151.81 | $12.99 |
| 52 Week High | $236.00 | $17.26 |
| Indicator | WAB | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 58.97 | 72.46 |
| Support Level | $227.08 | $16.63 |
| Resistance Level | $233.67 | $17.26 |
| Average True Range (ATR) | 4.10 | 0.24 |
| MACD | -0.23 | 0.05 |
| Stochastic Oscillator | 58.44 | 95.93 |
Westinghouse Air Brake Technologies Corp provides value-added, technology-based products and services for the freight rail and passenger transit industries and the mining, marine, and industrial markets. It provides its products and services through two main business segments: Freight and Transit. The company generates maximum revenue from the Freight segment, which manufactures new and modernized locomotives, provides aftermarket parts and services to existing locomotives, provides components to new and existing freight cars; builds new commuter locomotives; supplies rail control and infrastructure products, including electronics, positive train control equipment, signal design, and engineering services. Geographically, it generates a majority of its revenue from the United States.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.